Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:35:14 EDT Sun 25 Oct 2026
Enter Symbol
or Name
USA
CA



News last 24 hour(s) - 24 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-10-25 07:00U:NBPNews ReleaseNovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
2026-10-25 07:00U:GMABNews ReleaseGenmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
2026-10-25 07:00U:AGENNews ReleaseAgenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
2026-10-25 06:22U:BORRNews ReleaseBorr Drilling Limited - Prospector 5 Rig Incident
2026-10-25 05:15U:REGNNews ReleaseLibtayo(TM) (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
2026-10-25 04:35U:XNCRNews ReleaseXencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
2026-10-25 03:30U:LLYNews ReleaseNew data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
2026-10-25 03:30U:JNJNews ReleaseJohnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC(TM) molecule
2026-10-25 03:30U:BNTXNews ReleaseBioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
2026-10-24 23:57U:GXRFFNews ReleaseProspera Energy Announces Service Rig Update as Luseland Workovers Come Online at 3.3x Prior Rates
2026-10-24 20:00U:ELEKNews ReleaseFrom Record-High Market Excitement to American Lithium Ambition: Elektros Looks North
2026-10-24 19:30U:ELEKNews ReleaseWall Street Fever, an Early Christmas in October: Penny Stock Lovers, This Is Your Time To Shine
2026-10-24 19:30U:CLYMNews ReleaseClimb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
2026-10-24 16:06U:GGIINews ReleaseSiren's Tale Vodka to Exhibit at SoCal Cocktail and Spirits Fest
2026-10-24 15:19U:TECKNews ReleaseTeck Provides Update on Highland Valley Copper Operations
2026-10-24 13:00U:AXONNews ReleaseAxon Announces Body 5: Next-Generation Camera Built for the AI Era
2026-10-24 11:18U:PFENews ReleasePfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
2026-10-24 10:35U:AZNNews ReleaseIMFINZI(TM) (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
2026-10-24 10:30U:AZNNews ReleasePerioperative IMFINZI(TM) (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
2026-10-24 10:30U:AMGNNews ReleaseIMDELLTRA(TM) IN COMBINATION WITH IMFINZI(TM) REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
2026-10-24 08:45U:PBLSNews ReleaseParabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
2026-10-24 08:00U:SMTCNews ReleaseSemtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026
2026-10-24 08:00U:BAYZFNews ReleaseESMO 2026: NUBEQA(TM) (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence
2026-10-24 08:00U:BAYRYNews ReleaseESMO 2026: NUBEQA(TM) (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence